Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases
- PMID: 8706593
- DOI: 10.2165/00003495-199651040-00003
Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases
Abstract
The bisphosphonates are a class of synthetic compounds used in the treatment of various metabolic bone diseases, including hypercalcaemia of malignancy, Paget's disease, postmenopausal osteoporosis and corticosteroid-induced bone loss. Although there have been numerous studies comparing first, second and third generation bisphosphonates with placebo, there has been a paucity of comparative research investigating the effectiveness of these substances with other pharmacological agents. Still, the available evidence indicates that the bisphosphonates are well tolerated and effective therapeutic agents for various metabolic bone diseases. It seems certain that within the next 5 years, this class of drugs will emerge as one of the foremost options for treating Paget's disease and osteoporosis.
Similar articles
-
[Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].Rev Chir Orthop Reparatrice Appar Mot. 1998 Nov;84(8):743-51. Rev Chir Orthop Reparatrice Appar Mot. 1998. PMID: 10192126 Review. French.
-
Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.Bone. 1992;13(5):351-4. doi: 10.1016/8756-3282(92)90450-b. Bone. 1992. PMID: 1419375 Review. No abstract available.
-
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.Drugs. 2006;66(16):2031-58. doi: 10.2165/00003495-200666160-00001. Drugs. 2006. PMID: 17112299 Review.
-
Alendronate reaches U.S. market for osteoporosis, Paget's disease.Am J Health Syst Pharm. 1995 Nov 15;52(22):2513-4. doi: 10.1093/ajhp/52.22.2513. Am J Health Syst Pharm. 1995. PMID: 8590234 No abstract available.
-
Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.Drug Saf. 1994 Sep;11(3):179-95. doi: 10.2165/00002018-199411030-00004. Drug Saf. 1994. PMID: 7811400 Review.
Cited by
-
Bisphosphonate Treatment in a Patient Affected by MPS IVA with Osteoporotic Phenotype.Case Rep Med. 2013;2013:891596. doi: 10.1155/2013/891596. Epub 2013 Nov 18. Case Rep Med. 2013. PMID: 24348578 Free PMC article.
-
Bisphosphonate therapy for children and adolescents with secondary osteoporosis.Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD005324. doi: 10.1002/14651858.CD005324.pub2. Cochrane Database Syst Rev. 2007. PMID: 17943849 Free PMC article.
-
Alendronate inhibits periprosthetic bone loss around uncemented femoral components.J Bone Miner Metab. 2007;25(3):179-83. doi: 10.1007/s00774-006-0743-7. Epub 2007 Apr 20. J Bone Miner Metab. 2007. PMID: 17447116 Clinical Trial.
-
Bisphosphonates in bone diseases.Pharm World Sci. 1998 Oct;20(5):206-13. doi: 10.1023/a:1008626026484. Pharm World Sci. 1998. PMID: 9820883 Review.
-
Apoptosis in interface membranes of aseptically loose total hip arthroplasty.J Mater Sci Mater Med. 2001 Jul;12(7):653-8. doi: 10.1023/a:1011254029864. J Mater Sci Mater Med. 2001. PMID: 15348259
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical